Articles – PISCIS Cohort Poblacional de VIH CatalanoBalear

Martín-Iguacel R, Vazquez-Friol MC, Burgos J, Bruguera A, Reyes-Urueña J, Moreno-Fornés S, Aceitón J, Díaz Y, Domingo P, Saumoy M, Knobel H, Dalmau D, Borjabad B, Johansen IS, Miro JM, Casabona J, Llibre JM

Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study, Cardiovascular and HIV,Front Med (Lausanne). 2023 Jun 21;10:1182359.

DOI: 10.3389/fmed.2023.1182359.

Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J

Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands, HIV, Int J Epidemiol. 2023 Jul 4:dyad083.

DOI: 10.1093/ije/dyad083.

Mesías-Gazmuri J, Folch C, Palacio-Vieira J, Bruguera A, Egea-Cortés L, Forero CG, Hernández J, Miró JM, Navarro J, Riera M, Peraire J, Alonso-García L, Díaz Y, Casabona J, Reyes-Urueña J.

Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study, Syndemic conditions,Health Qual Life Outcomes. 2023 May 30;21(1):53.

DOI: 10.1186/s12955-023-02139-5

Nomah DK, Díaz Y, Vivanco-Hidalgo RM, Casabona J, Miro JM, Reyes-Urueña J; COVID-19-PISCIS research group.

Population-based assessment of SARS-CoV-2 infection among people living with HIV and the general population of Catalonia (March-December, 2020), AIDS; COVID-19; HIV; SARS-CoV-2,Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr 17:S2529-993X(23)00094-1.

DOI: 10.1016/j.eimce.2022.02.017

Palacio-Vieira J, Moreno-Fornés S, Díaz Y, Aceitón J, Bruguera A, Nomah DK, Llibre JM, Knobel H, Chivite I, Miro JM, Domingo P, Suanzes P, Fanjul F, Navarro G, Macorigh L, Mera A, Casabona J, Imaz A, Reyes-Urueña J; PISCIS study group

Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort, COVID-19; HIV; loss to follow-up,HIV Med . 2023 Mar 29.

DOI: 10.1111/hiv.13486.

Greenberg L, Ryom L, Neesgaard B, Miró JM, Rasmussen LD, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A; RESPOND Study Group

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting, Cancer; integrase inhibitors,Open Forum Infect Dis . 2022 Jan 19;9(3):ofac029.

DOI: 10.1093/ofid/ofac029

Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti A, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group

Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens, HIV mortality,J Antimicrob Chemother . 2022 Dec 23;78(1):108-116.

DOI: 10.1093/jac/dkac361.

Nomah DK, Llibre JM, Díaz Y, Moreno S, Aceiton J, Bruguera A, Gutiérrez-Macià M, Imaz A, Suanzes P, Navarro G, Orti A, Miro JM, Casabona J, Reyes-Urueña J, The Piscis Study Group

SARS-CoV-2 Vaccination Coverage and Factors Associated with Low Uptake in a Cohort of People Living with HIV, SARS-CoV-2; HIV,Microorganisms . 2022 Aug 18.

DOI: 10.3390/microorganisms10081666.

Martin-Iguacel R, Reyes-Urueña J, Bruguera A, Aceitón J, Díaz Y, Moreno-Fornés S, Domingo P, Burgos-Cibrian J, Tiraboschi JM, Johansen IS, Álvarez H, Miró JM, Casabona J, Llibre JM; PISCIS study group

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study, Delayed HIV diagnosis; HIV; mortality,EClinicalMedicine. 2022 Aug 3

DOI: 10.1016/j.eclinm.2022.101600

Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group

Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study, SARS-COV-2 and HIV,J Antimicrob Chemother. 2022 Jul 28

DOI: 10.1093/jac/dkac177

The RESPOND Study Group

Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents, HIV,AIDS . 2021 May 1;35(6):869-882.

DOI: 10.1097/QAD.0000000000002811.

Palacio-Vieira J, Maria Reyes-Urueña J, Imaz A, Bruguera A, Force L, Orti Llaveria A, Llibre JM, Vilaró I, Homar Borràs F, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J, PICIS study group

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review, HIV care,BMC Public Health . 2021 Aug 28;21(1):1596.

DOI: 10.1186/s12889-021-11613-y.

Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, Guaraldi G, Vehreschild JJ, Wit F, Law M, Wasmuth JC, Chkhartishvili N, d'Arminio Monforte A, Fontas E, Vesterbacka J, Miro JM, Castagna A, Stephan C, Llibre JM, Neesgaard B, Greenberg L, Smith C, Kirk O, Duvivier C, Dragovic G, Lundgren J, Dedes N, Knudsen A, Gallant J, Vannappagari V, Peters L, Elbirt D, Sarcletti M, Braun DL, Necsoi C, Mussini C, Muccini C, Bolokadze N, Hoy J, Mocroft A, Ryom L

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium, Antiretrovirals,Lancet HIV. 2021 Nov;8(11):e711-e722.

DOI: 10.1016/S2352-3018(21)00163-6

Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM, PISCIS study group

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study, COVID-19 and VIH,Lancet HIV. 2021 Nov;8(11)

DOI: 10.1016/S2352-3018(21)00240-X

Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Günthard HF, Necsoi C, Law M, Mussini C, Castagna A, d'Arminio Monforte A, Pradier C, Chkhartisvilli N, Reyes-Uruena J, Janne Vehreschild J, Wasmuth JC, Sönnerborg A, Stephan C, Greenberg L, Llibre JM, Volny-Anne A, Peters L, Pelchen-Matthews A, Vannappagari V, Gallant J, Rieger A, Youle M, Braun D, De Wit S, Petoumenos K, Borghi V, Spagnuolo V, Tsertsvadze T, Lundgren J, Ryom L, RESPOND study group.

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium, Virology,PLoS One . 2020 Dec 31;15(12):e0243625.

DOI: 10.1371/journal.pone.0243625

The Respond Study Group

How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium, HIV; cohort; hepatitis,Microorganisms. 2020 Jul 31;8(8):1164.

DOI: 10.3390/microorganisms8081164

Trickey A, van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, et al.

Parameter estimates for trends and patterns of excess mortality among persons on ART in high-income european settings, AIDS, 2019 Nov 19.

DOI: 10.1097/QAD.0000000000002387

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, et al.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals, Statistics in medicine, 2019 Jun 15;38(13):2428-2446.

DOI: 10.1002/sim.8120

Llibre JM, Montoliu A, Miró JM, Domingo P, Riera M, Tiraboschi J, et al.; PISCIS Cohort group.

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort, HIV Medicine, 2019 Mar;20(3):237-247.

DOI: 10.1111/hiv.12710

Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, et al.; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord.

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis, Journal of Viral Hepatitis, 2019 Oct;26(10):1224-1228.

DOI: 10.1111/jvh.13146

Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, et al.; INSIGHT START Study Group and the HIV-CAUSAL Collaboration.

Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples, American Journal of Epidemiology, 2019 Aug 1;188(8):1569-1577.

DOI: 10.1093/aje/kwz100

Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?, HIV Med., 2018 Jan;19(1):42-48.

DOI: 10.1111/hiv.12536.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, et al.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions, J Acquir Immune Defic Syndr.,2018 Jan 1;77(1):102-109.

DOI: 10.1097/QAI.0000000000001562.

Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, et al.; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation, J Int AIDS Soc,2018 Jan;21(1)

DOI: 10.1002/jia2.25031.

Young J, Smith C, Teira R, Reiss P, Jarrín Vera I, Crane H, et al.

Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection, HIV Med, 2018 Feb;19(2):132-142.

DOI: 10.1111/hiv.12562.

Reyes-Urueña JM, Campbell CNJ, Vives N, Esteve A, Ambrosioni J, Tural C, et al. ; PISCIS investigators.

Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population., BMJ open 8.2, 2018 Feb 28;8(2):e018533

DOI: 10.1136/bmjopen-2017-018533.

Conway A, Esteve A, Fernández-Quevedo M, Casabona J; PISCIS Study Group

Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004–2016, Journal of immigrant and minority health, 2018 Oct; 30: 1-11

DOI: 10.1007/s10903-018-0834-2

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, et al.

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older, J Acquir Immune Defic Syndr,2017;76(3):311–8.

DOI: 10.1097/QAI.0000000000001498.

Chêne G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, et al.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Int J Epidemiol,2017 Jun 1;46(3):797-797n.

DOI: 10.1093/ije/dyw211.

Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, et al.; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients, HIV Med,2017 Jan;18(1):33-44.

DOI: 10.1111/hiv.12389.

Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe, AIDS,2017 Mar 27;31(6):835-846.

DOI: 10.1097/QAD.0000000000001411.

Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, et al.; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study, Ann Intern Med,2017 Jan 3;166(1):9-17.

DOI: 10.7326/M16-0240.

Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, et al.; Pursuing Later Treatment Options II (PLATO II) Project Team for the COEHERE in EuroCoord.

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe, HIV Med.,2017 Mar;18(3):171-180.

DOI: 10.1111/hiv.12411.

Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, et al.; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers, PLoS One,2017 Apr 5;12(4):e0173893.

DOI: 10.1371/journal.pone.0173893.

Hepatitis C Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients?, AIDS,2017 Mar 13;31(5):661-668.

DOI: 10.1097/QAD.0000000000001378.

Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Coord.

Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe, AIDS,2017 Jan 14;31(2):253-262.

DOI: 10.1097/QAD.0000000000001270.

Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, et al.; HIV-CAUSAL Collaboration.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study, Lancet HIV,2017 Jun;4(6):e251-e259.

DOI: 10.1016/S2352-3018(17)30043-7.

AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study, Clin Infect Dis.,2017 Oct 15;65(8):1316-1326.

DOI: 10.1093/cid/cix480.

Antiretroviral Therapy Cohort Collaboration

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV, 2017 Aug;4(8):e349-e356

DOI: 10.1016/S2352-3018(17)30066-8.

Antiretroviral Therapy Cohort Collaboration (ART-CC); Canadian Observational Cohort Collaboration (CANOC); UK Collaborative HIV Cohort Study (UK CHIC); Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis, AIDS,2016 Jan 28;30(3):503-13.

DOI: 10.1097/QAD.0000000000000941.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, et al.; CHAIN and COHERE in EuroCoord

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen, J Antimicrob Chemother,2016 May;71(5):1352-60.

DOI: 10.1093/jac/dkv465.

Nicolás D, Esteve A, Cuadros A, Campbell CN, Tural C, Podzamczer D, et al.; PISCIS Cohort Study Investigators

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection, Clin Infect Dis,2016 Jun 15;62(12):1578-85.

DOI: 10.1093/cid/ciw157.

Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, et al.; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collabor

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study, J Acquir Immune Defic Syndr,2016 Jun 1;72(2):214-21.

DOI: 10.1097/QAI.0000000000000956.

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, et al.; HIV-CAUSAL Collaboration.

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals, Medicine (Baltimore),2016 Oct;95(41):e5133.

DOI: 10.1097/MD.0000000000005133

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia, Clin Infect Dis,2016 Nov 1;63(9):1245-1253.

DOI: 10.1093/cid/ciw519.

Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy, Int J Epidemiol,2016 Dec 1;45(6):2038-2049.

DOI: 10.1093/ije/dyv295.

Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, et al.; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults, AIDS,2015 Jan 14;29(2):193-200.

DOI: 10.1097/QAD.0000000000000530.

The Antiretroviral Therapy Cohort Collaboration (ART-CC)

Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US, Antivir Ther,2015;20(1):21-8.

DOI: 10.3851/IMP2768.

HIV-CAUSAL Collaboration

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries, Clin Infect Dis,2015 Apr 15;60(8):1262-8.

DOI: 10.1093/cid/ciu1167.

Antiretroviral Therapy Cohort Collaboration (ART-CC)

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients, AIDS,2015 Jan 28;29(3):373-83.

DOI: 10.1097/QAD.0000000000000544.

May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, et al.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration, J Acquir Immune Defic Syndr,2015 Jul 1;69(3):348-54.

DOI: 10.1097/QAI.0000000000000603.

Late presenters working group in COHERE in EuroCoord

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013, Euro Surveill,2015 Nov 26;20(47).

DOI: 10.2807/1560-7917.ES.2015.20.47.30070.

Migrants Working Group on behalf of COHERE in EuroCoord

Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study, Lancet HIV,2015 Dec;2(12):e540-9.

DOI: 10.1016/S2352-3018(15)00203-9.

Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, et al.; PISCIS Investigators

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status, J Antimicrob Chemother,2015 Dec;70(12):3332-8.

DOI: 10.1093/jac/dkv272.

HIV-CAUSAL Collaboration

omparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study, Lancet HIV,2015 Aug;2(8):e335-43.

DOI: 10.1016/S2352-3018(15)00108-3.

Hepatitis C- working group for COHERE in Eurocoord

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord, BMC Infect Dis,2015 Nov 4;15:498.

DOI: 10.1186/s12879-015-1224-1.

Campbell CN, Ambrosioni J, Miro JM, Esteve A, Casabona J, Navarro G, et al.

The continuum of HIV care in Catalonia, AIDS Care,2015 Dec;27(12):1449-54.

DOI: 10.1080/09540121.2015.1109584.

Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, et al.

Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, AIDS,2015 Jan 14;29(2):221-9.

DOI: 10.1097/QAD.0000000000000540.

IeDEA and ART Cohort Collaborations

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries, J Acquir Immune Defic Syndr,2014 Jan 1;65(1):e8-16.

DOI: 10.1097/QAI.0b013e3182a39979.

May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al.; the Antiretroviral Cohort Collaboration

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC), Int J Epidemiol,2014 Jun;43(3):691-702.

DOI: 10.1093/ije/dyt010.

Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al.; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

ong-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery, Clin Infect Dis,2014 May;58(9):1312-21.

DOI: 10.1093/cid/ciu038.

Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, et al.; HIV-CAUSAL Collaboration

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions, Neurology,2014 Jul 8;83(2):134-41.

DOI: 10.1212/WNL.0000000000000564.

The Natural History Project Working Group* for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals, AIDS,2014 Jun 1;28(9):1351-6.

DOI: 10.1097/QAD.0000000000000224.

Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al.; Antiretroviral Therapy Cohort Collaboration

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients, Clin Infect Dis,2014 Jul 15;59(2):287-97.

DOI: 10.1093/cid/ciu261.

The HIV-CAUSAL Collaboration !!!!!!!!!!!!!!!!!!!!!!!

Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries, AIDS,2014 Oct 23;28(16):2461-73.

DOI: 10.1097/QAD.0000000000000456.

Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord, AIDS,2014 Sep 24;28(15):2297-306.

DOI: 10.1097/QAD.0000000000000410.

Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, et al.

Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies, PLoS Med,2014 Sep 9;11(9):e1001718.

DOI: 10.1371/journal.pmed.1001718.

Stuardo V, Agustí C, Casabona J; HPV-PISCIS Study Group

Low Prevalence of Cervical Cancer Screening Among HIV-Positive Women in Catalonia, J Aids Clin Res,2013 S3: 004.

DOI: 10.4172/2155-6113.S3-004.

Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes, J Infect Dis,2013 Mar;207(5):759-67.

DOI: 10.1093/infdis/jis752.

The Antiretroviral Therapy Cohort Collaboration (ART-CC)

Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis, AIDS,2013 May 15;27(8):1321-9.

DOI: 10.1097/QAD.0b013e32835faa95.

The Antiretroviral Therapy Cohort Collaboration (ART-CC)

Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States, Clin Infect Dis,2013 Jun;56(12):1800-9.

DOI: 10.1093/cid/cit111.

Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, et al.; Writing committee for the Antiretroviral Cohort Collaboration

Insurability of HIV positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies, AIDS,2013 Jun 19;27(10):1641-55.

DOI: 10.1097/QAD.0b013e3283601199.

Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, et al.; PISCIS Cohort Investigators

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort, Clin Microbiol Infect,2013 Jul;19(7):646-53.

DOI: 0.1111/j.1469-0691.2012.03991.x.

Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, et al.; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE), PLoS Med,2013 Sep;10(9):e1001510.

DOI: 10.1371/journal.pmed.1001510.

Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al.; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research EuroCOORD

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era, Clin Infect Dis,2013 Oct;57(7):1038-47.

DOI: 10.1093/cid/cit423.

Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, et al.; Antiretroviral Therapy Cohort Collaboration (ART-CC)

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009, AIDS,2013 Mar 13;27(5):803-13.

DOI: 10.1097/QAD.0b013e32835cb997.

Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, et al.; for the Antiretroviral Therapy Cohort Collaboration (ART-CC)

The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis, HIV Med,2012 Feb;13(2):89-97.

DOI: 10.1111/j.1468-1293.2011.00940.x.

The Pursuing Later Treatment Option II (PLATO II) project team* for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, Lancet Infect Dis,2012 Feb;12(2):119-27.

DOI: 10.1016/S1473-3099(11)70248-1.

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

CD4 cell count and the risk of AIDS or death in HIV infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, PLoS Med,2012 Mar;9(3):e1001194.

DOI: 10.1371/journal.pmed.1001194.

The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe, J Acquir Immune Defic Syndr,2012 Mar 1;59(3):294-9.

DOI: 10.1097/QAI.0b013e31823fe66b.

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared with the general population: evidence from a large European observational cohort collaboration, Int J Epidemiol,2012 Apr;41(2):433-445.

DOI: 10.1093/ije/dyr164.

The HIV-CAUSAL Collaboration

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries, Clin Infect Dis,2012 May;54(9):1364-72.

DOI: 10.1093/cid/cis203.

The HIV-CAUSAL Collaboration

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study, AIDS,2012 Aug 24;26(13):1691-705.

DOI: 10.1097/QAD.0b013e328354f497.

HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration, Antivir Ther,2012;17(8):1541-50.

DOI: 10.3851/IMP2263.

Stuardo V, Agustí C, Godinez JM, Montoliu A, Torné A, Tarrats A, et al.

Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer, PLoS One,2012;7(10):e47755.

DOI: 10.1371/journal.pone.0047755.

Antiretroviral Cohort Collaboration

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics, Int J Epidemiol,2012 Dec; 41(6):1807-20.

DOI: 10.1093/ije/dys164

The HIV - CAUSAL Collaboration

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries. an observational study. An observational study, Ann Intern Med,2011 Apr 19;154(8):509-15.

DOI: 10.7326/0003-4819-154-8-201104190-00001.

Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al.; for the EuroCoord-CHAIN study group

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study, Lancet Infect Dis,2011 May;11(5):363-71.

DOI: 10.1016/S1473-3099(11)70032-9.

The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

Risk of triple-class virological failure in children with HIV: a retrospective cohort study, Lancet,2011 May 7;377(9777):1580-7.

DOI: 10.1016/S0140-6736(11)60208-0.

Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, et al.; Collaboration of Observational HIV Epidemiological Research Europe

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes, Blood,2011 Jun 9;117(23):6100-8.

DOI: 10.1182/blood-2010-08-301531.

Young JG, Cain LE, Robins JM, O’Reilly EJ, Hernán MA

Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula, Stat Biosci,2011 Sep 1;3(1):119-143.

DOI: 10.1007/s12561-011-9040-7.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, et al.; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study, J Acquir Immune Defic Syndr,2011 Nov 1;58(3):253-60.

DOI: 10.1097/QAI.0b013e318230372e.

The HIV-CAUSAL Collaboration

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals, AIDS,2010 Jan; 24(1):123-37.

DOI: 10.1097/QAD.0b013e3283324283.

The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Arch Intern Med,2010 Mar 8;170(5):410-9.

DOI: 10.1001/archinternmed.2009.472.

The Antiretroviral Therapy Cohort Collaboration

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996 – 2006: collaborative analysis of 13 HIV cohort studies, Clin Infect Dis,2010 May 15;50(10):1387-96.

DOI: 10.1086/652283.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients

Death rates in HIV-positive antiretroviral-naive patients with with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study, Lancet,2010 Jul 31;376(9738):340-5.

DOI: 10.1016/S0140-6736(10)60932-4.

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/mL?, Clin Infect Dis,2010 Sep 1;51(5):611-9.

DOI: 10.1086/655761.

Betancourt A, Ortega N.

Tractament antiretroviral de les persones que viuen amb el VIH a Catalunya. Dades de la Cohort PISCIS, 1998-2006, Infosida,2009; 39.

Collaboration of Observation HIV Epidemiological Research Europe (COHERE)

Incidence and risk factors of HIV-associated non-Hodgkin lymphoma in the era of combination antiretroviral therapy. European multi-cohort study, Antivir Ther,2009;14(8):1065-74.

DOI: 10.3851/IMP1462.

The Antiretroviral Therapy (ART) Cohort Collaboration

Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy. Not All AIDS-Defining Conditions Are Created Equal, Clin Infect Dis,2009 Apr 15;48(8):1138-51.

DOI: 10.1086/597468.

The Antiretroviral Therapy (ART) Cohort Collaboration

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1 infected people: a collaborative analysis of 18 HIV cohort studies, Lancet,2009 Apr. 18;373(9672):1352-63.

DOI: 10.1016/S0140-6736(09)60612-7.

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, Int J Epidemiol,2009 Sep 24; 38:1624-33.

DOI: 10.1097/QAD.0b013e32832e531c.

The antiretroviral therapy cohort collaboration (ART-CC)

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements, AIDS,2009 Oct 23;23:2199-208.

DOI: 10.1097/QAD.0b013e3283305a00.

The Antiretroviral Therapy (ART) Cohort Collaboration

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression, J Acquir Immune Defic Syndr,2009 Nov. 1;52(3):357-63.

DOI: 10.1097/QAI.0b013e3181b62933.

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy, AIDS,2009 Sep 24;23(15):2029-37.

DOI: 10.1097/QAD.0b013e32832e531c.

Jaen A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, et al.; PISCIS Study Group

Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy. PISCIS Cohort (Spain), J Acquir Immune Defic Syndr,2008 Feb 1;47(2):212-20.

DOI: #

The Antiretroviral Therapy (ART) Cohort Collaboration

Does short-term virologic failure translate to clinical events in ARV-naïve patients initiating ART in clinical practice?, AIDS,2008 Nov 30;22(18):2481-92.

DOI: 10.1097/QAD.0b013e328318f130.

Navarro G, Nogueras MM, Segura F, Casabona J, Miro JM, Murillas J, et al.; PISCIS Study group

HIV-1 infected patients older than 50 years. PISCIS cohort study, J Infect,2008 Jul;57(1):64-71.

DOI: 10.1016/j.jinf.2008.05.003.

The Antiretroviral Therapy (ART) Cohort Collaboration

Life expectancy of individuals on combination antiretroviral therapy in high-income countries. A collaborative analysis of 14 cohort studies, Lancet,2008 Jul 26;372(9635):293-9.

DOI: 10.1016/S0140-6736(08)61113-7.

The Collaboration of Observation HIV Epidemiological Research Europe (COHERE)

Response to combination antiretroviral therapy: variation by age, AIDS,2008 Jul 31;22(12):1463-73.

DOI: 10.1097/QAD.0b013e3282f88d02.

Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al.; Antiretroviral Therapy Cohort Collaboration

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies, Antivir Ther,2008;13(8):959-67.

DOI: #

Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA); ART Cohort Collaboration

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries, Clin Infect Dis,2007 Dec 1;45(11):1518-21.

DOI: 10.1086/522986.

Antiretroviral Therapy Cohort Collaboration

Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1 infected patients, J Acquir Immune Defic Syndr,2007 Dec 15;46(5):607-15.

DOI: 10.1097/QAI.0b013e31815b7dba.

May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, et al.; Antiretroviral Therapy (ART) Cohort Collaboration

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies, AIDS,2007 May 31;21(9):1185-97.

DOI: 10.1097/QAD.0b013e328133f285.

Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R, et al.; Grupo de trabajo de la Cohorte de la Red de Investigación en Sida (CoRIS)

Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados, Enferm Infecc Microbiol Clin,2007;25(1):23-31.

May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al.; Antiretroviral Therapy (ART) Cohort Collaboration

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis, Lancet,2006 Aug 5;368(9534):451-8.

DOI: 10.1016/S0140-6736(06)69152-6

Jaen A, Casabona J, Esteve A, Miro JM, Tural C, Ferrer E, et al.

Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS, Med Clin (Barc),2005;124(14):525-31.

Jaén A.

Coinfecció per VIH i pels virus de les Hepatitis B i C. Cohort PISCIS, Infosida,2005; 31.